Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Leukemia. 2008 Jul 10;23(2):402–404. doi: 10.1038/leu.2008.185

Fig 1. Association of rs12459419 (Ala14Val) polymorphism with response to GO in pediatric patients with AML.

Fig 1

(A) Change in the MRD of patients with AML after treatment including GO, according to number of T alleles (Val) in rs12459419. ○ indicates measure of change in MRD for patients with AML who received ADE+GO; Δ indicates measure of change in MRD for patients with AML who received GO. P=0.026. (B) MRD levels in leukemic blasts pre and post treatment with GO containing regimens in 22 patients with AML. The lines joining the MRD levels of patients also depict the genotype for rs12459419 as shown in the inset.